After 14 total years affiliated with the University of Pittsburgh as graduate student and faculty member, T32 alumnus Andrew D. Althouse, PhD (Epidemiology, 2013) was hired as a Senior Principal Statistician by Medtronic in October 2022 with the aim of working on groundbreaking clinical trials in the field of structural heart disease. The first trial he was assigned to at Medtronic was the SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial (SMART), the first randomized comparison of the two leading platforms for transcatheter aortic valve replacement (TAVR). After years of painstaking work, the final data lock was executed in November 2023 and the results presented at the 2024 American College of Cardiology meetings, with a simultaneous publication in the New England Journal of Medicine (the full citation for the NEJM publication is available below). Congratulations to Dr. Althouse on this incredible accomplishment!
Herrmann HC, Mehran R, Blackman DJ, Bailey S, Möllmann H, Abdel-Wahab M, Ben Ali W, Mahoney PD, Ruge H, Wood DA, Bleiziffer S, Ramlawi B, Gada H, Petronio AS, Resor CD, Merhi W, Garcia Del Blanco B, Attizzani GF, Batchelor WB, Gillam LD, Guerrero M, Rogers T, Rovin JD, Szerlip M, Whisenant B, Deeb GM, Grubb KJ, Padang R, Fan MT, Althouse AD, Tchétché D. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med 2024 (epub ahead of print) PMID: 38587261